In conclusion, our findings suggest that SGLT2 inhibitor use was associated with a significant reduction in the risk of incident heart failure and adverse cardiovascular outcomes such as incident AF, cardiac arrest, ischaemic stroke/TIA and arterial and venous thrombosis, although no differences were observed for ventricular arrhythmias. The gene discussed is SLC5A2; the disease is cardiac arrest.